Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

Provided herein is a cell macroencapsulation device composed of hydrogel in a 3D conformation that optimizes encapsulated cell viability and function when transplanted into a vascularized tissue space. The hydrogel macroencapsulation device is intended to reduce or eliminate immune response to the cell graft, while allowing exchange of encapsulated cell-secreted products, such as insulin. Also described herein is an injection-mold and fabrication process to generate the hydrogel macroencapsulation devices for use in the clinic.

Genetically modified cells, tissues, and organs for treating or preventing diseases are disclosed. Also disclosed are methods of making the genetically modified cells and non-human animals.

Methods are provided for the simple, fast, effective and safe directed differentiation of embryonic stem cells into pancreatic beta-like cells secreting insulin in response to glucose levels. The cells are useful transplant therapeutics for diabetic individuals.

Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Systems and methods for multilane vasculature and multiorgan vascular-vessel fluidic interfaces in in vitro models. The method includes embedding at least one tissue into a 3D structure, forming a vascular interface for nutrient perfusion into the tissue or tissues, tuning the vascular interface or interfaces together or separately to possess a property of a native biological target tissue or target environment by modifying a vessel attribute; and lining a fluidic interface channel, for providing a growth fluid in a physiologically recapitulating manner. The 3D structure includes a vasculogenic element for angiogenesis or vasculogenesis.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

Provided herein, inter alia, are compositions and methods for culturing islet cells.

Disclosed herein are methods for generating SC- cells, and isolated populations of SC- cells for use in various applications, such as cell therapy.

An object of the present invention is to provide a method for removing highly proliferative Ki67-positive cells co-present in insulin-secreting cells obtained by differentiation induction. A method for producing an insulin-producing cell population or a pancreatic beta cell population containing less than 3% of Ki67-positive cells, comprising: embedding an endocrine progenitor cell population or a cell population at a later stage of differentiation into a gel containing alginic acid; and differentiating the cell population.